Recent studies based in active targeted liposomes for CNS diseases.
Central nervous system diseases represent a huge world of burden of human suffering with negative economic results. Most therapeutic compounds cannot attain the brain because of the blood-brain barrier and its expression of efflux transporters. Among them, the P-glycoprotein plays a significant role leading to failure of various clinical treatments. A non-invasive strategy to circumvent the blood-brain barrier and P-glycoprotein emphasizes on the encapsulation and therefore masking of therapeutic compounds in drug delivery systems. Up to now, liposomes are the most widely studied drug delivery systems due to their biocompatibility, biodegradability, and less toxicity. The incorporation of polyethylene glycol-lipid derivatives within the bilayer of conventional liposomes significantly prolongs liposomal cargo half-life by steric stabilization. Interestingly, an increased brain accumulation of liposomal cargo is achieved by coupling targeting moieties on liposomes surface. These targeting moieties such as peptides or monoclonal antibodies recognize the biochemical transport systems at the blood-brain barrier and mediate the transport of liposomes and their cargo across this barrier. Moreover, stimuli-sensitive liposomes are programmed for cargo release when exposed to a particular microenvironment. Hence, this chapter highlights the potential liposomal applications for delivery of therapeutic compounds as well as diagnostic tools or both, in major central nervous system diseases.
- central nervous system diseases
- blood-brain barrier
- passive targeting
- active targeting
- stimuli strategies
Most neurological disorders compromise the central nervous system (CNS) and its main organ, the brain. These disorders include stroke, brain cancer, Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, neuroinfections, and traumatic disorders of the nervous system, among others (http://www.who.int/en/). Because millions of people worldwide are affected by CNS disorders, they constitute 6.3% of the global burden of disease. In other words, CNS diseases are a huge world of burden of human suffering with negative economic results . Most of the therapeutic molecules cannot attain the brain because of the presence of the blood-brain barrier (BBB), which separates the bloodstream from the cerebral parenchyma . This barrier is mainly composed by endothelial cells, which are linked by tight junctions . The BBB also contains a basal membrane, pericytes, and astrocytes . More important is the presence of efflux transporters that perform active back-transport of the therapeutic molecules to the blood lumen. P-glycoprotein (P-gp) is the most important efflux transporter associated to the failure of various therapies to treat CNS diseases . Advances in nanomedicine have created a non-invasive strategy for the management of CNS diseases . This strategy emphasizes on the encapsulation of therapeutic compounds, which are mainly P-gp substrates, in drug delivery systems, also called nanocarriers, such as liposomes, lipid nanocapsules, polymeric nanoparticles, or polymersomes [6–10]. Encapsulation of therapeutic compounds in drug delivery systems improve their solubility and protect them from the biological environment and circumvent the P-gp at the BBB yielding higher concentrations of the therapeutic compounds in the brain parenchyma . Among nanocarriers, liposomes have been the most studied due to their composition, which makes them biocompatible, biodegradable, and less toxic . Liposomes not only hold potential as vehicles for therapeutic compounds (therapeutics)  but also for diagnostic tools (diagnostics)  directed to the CNS. Interestingly, recent efforts have combined therapeutics and diagnostics in the same unique nanocarrier, thus opening the way to theranostic liposomes, which represent an essential advancement for personalized nanomedicine . To specifically target the therapeutic compound or the diagnostic tool to the pathological site, the CNS, two strategies are usually used : (1) Passive targeting based on the longevity of the pharmaceutical carrier in the blood and its accumulation in pathological sites with compromised vasculature via the enhanced permeability and retention effect and (2) Active targeting based on the attachment of specific ligands to nanocarriers surface to recognize and bind specific biological receptors expressed at the BBB . Later studies propose a new active targeting strategy in which liposomes take advantage of changes in the pathological microenvironment for localized and timely release of their cargo . According to their formulation, stimuli-sensitive liposomes release may obey to internal stimuli such as pH, temperature, redox condition, and enzymatic activity or external stimuli such as magnetic fields, ultrasound, or irradiation . Since innovative strategies are urgently needed to counteract CNS diseases, this manuscript summarizes the most relevant examples of passively and actively targeted liposomes, smaller than 200 nm, for therapeutics, diagnostics, or theranostics of major CNS diseases.
2. The blood-brain barrier
The blood-brain barrier (BBB) is an innate and selective barrier formed by endothelial cells lining ~650 km of microvessels, which constitute by far the largest interface for the blood-brain exchange (Figure 1) . The BBB endothelial cells differ from endothelial cells in the rest of the body by the absence of fenestrations and sparse pinocytic vesicular transport. The BBB endothelial cells display wider tight junctions known as zonulae occludens, and adherens junctions (AJ), which cover the vessels walls as a continuous sheath, leaving no space between cells . Moreover, the BBB is also composed by an extracellular matrix (basal membrane), pericytes, and astrocyte foot processes [2, 4]. Because of this configuration, most molecular traffic takes a transcellular route across the BBB, rather than moving paracellularly as in most endothelia. The presence of specific transport systems on the luminal and abluminal membranes regulates the influx and efflux of various essential endogenous and exogenous substrates [17, 18]. Small gases such as oxygen and carbon dioxide but also small lipophilic agents, such as ethanol, caffeine, nicotine, and drugs like anesthetics and barbiturates, can diffuse freely through the lipid membranes . Small polar molecules, such as glucose, amino acids, organic anions and cations, and nucleosides cross the BBB by carrier-mediated transport. Large solutes, such as proteins and peptides, are transported across the BBB by receptor-mediated or adsorption-mediated endocytic transport [17, 18]. In parallel, it was originally stated that therapeutic compounds transporting across the BBB were dependent on their physicochemical properties such as lipophilicity, molecular weight, and ionic state. However, it is the presence of efflux transporters at the BBB that limits the brain uptake of a variety of endogenous and exogenous compounds, including relatively lipophilic therapeutic compounds . Most of these efflux transporters belong to the ATP-binding cassette (ABC) transporters super family. ABC transporters are transmembrane proteins that use the energy from the ATP hydrolysis to drive the efflux of their substrates. Based on three critical defining criteria, multi-specificity, location, and energetics; P-glycoprotein is considered to be the most important ABC efflux transporter at the BBB .
3. The P-glycoprotein
The expression of P-glycoprotein (P-gp) on endothelial cells at the human BBB was first described in 1989 by Cordon-Cardo et al. and Theibaut et al. [22, 23]. Since then, P-gp has been found at the luminal membrane of the endothelial cells lining the capillaries of the brain [4, 24], in neurons and in astrocytes [25, 26]. The P-gp is also localized at the apical surfaces of the epithelial cells that constitute the ventricular exposed surface of the human choroid plexus . The P-gp was also observed in primary brain tumors . The relevance of the P-gp at the BBB has been properly illustrated in knockout mice lacking the P-gp isoform mdr1a (mdr1a (−/−) mice). The mdr1a (−/−) mice were healthy and fertile and appeared phenotypically normal, but they accumulated much higher levels of P-gp substrates in the brain. A clear example was the increased sensitivity to the centrally neurotoxic pesticide ivermectin . Knockout mice accumulated 100-fold higher concentrations of ivermectin in the brain as compared to wild-type mice; consequently, knockout mice developed a severe neurotoxicity and died . More recently, selamectin, another pesticide also demonstrated to be a P-gp substrate . Meanwhile, pharmacokinetic studies in knockout mice were rapidly extended to therapeutic drugs. Thus, the absence of mdr1a in mice led to highly increased levels of vinblastine, digoxin, and cyclosporin A in the brain . Tissue distribution studies demonstrated that the relative brain penetration of radiolabeled ondansetron and loperamide is increased 4- and almost 14-fold, respectively in mdr1a (−/−) mice. Moreover, a pilot toxicity study showed that the oral administration of loperamide gains potent opiate-like activity in the CNS of mdr1a (−/−) mice. Oral domperidone also showed neuroleptic-like side effects in mdr1a (−/−) mice . Using the same
4. Circumventing the BBB
Disruption of the BBB has been observed in various CNS pathologies such as stroke, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) . From these scenarios, it is known that disruption of the BBB leads to increased extravasation of immune cells and poorly regulated flux of molecules and ions across the BBB with consequent neuroinflammation, neurodegeneration, or infections . Additionally, clinical disruption of the BBB is expensive and requires hospitalization . Therefore, in diseases where the BBB represents an obstacle to attain significant brain concentrations of therapeutic compounds, a less aggressive alternative is by modulating the activity of the P-gp. Nonetheless, we cannot negligate that the P-gp protects the brain from intoxication by endogenous and exogenous harmful lipophilic compounds that otherwise could penetrate the BBB by simple diffusion without any limitation . Therefore, the ideal approach should inhibit the P-gp at the BBB to let the P-gp substrate (therapeutic compound) enter into the brain and then re-induce the P-gp-mediated efflux to hamper the entry of harmful compounds. The development of third-generation P-gp modulators, which transiently and directly inhibit the transport of P-gp substrates, has been a promising approach to modulate the P-gp [37, 38]. Unfortunately, clinical studies suggest high doses of these compounds. These high doses by themselves or in co-administration with P-gp substrates may predict toxic profiles, thus limiting the use of these agents . Several studies have already proposed the use of natural products, the designs of peptidomimetics, and dual activity ligands as a fourth-generation of P-gp modulators . In spite of the countless studies, the effective and safe inhibition of the P-gp at the human BBB is not yet a reality. A non-invasive strategy that takes advantage of the CNS physiology involves nanomedicine . This innovative strategy uses mainly nano-scale drug delivery systems (DDSs) such as liposomes, polymeric nanoparticles, lipid nanocapsules, and polymersomes. Hereafter, DDSs transport small doses of poorly soluble drugs through the body and by-pass the P-gp at the BBB to finally target the brain, thus reducing toxicity in peripheral tissues . A synergistic strategy that had obtained optimistic
5. Liposomal strategies to target the central nervous system
Nanotechnology is the understanding and control of matters having dimensions roughly within the 1–100 nm range. However, in nanomedicine, particles smaller than 10 nm are quickly cleared by the kidney or through extravasation and particles bigger than 200 nm are efficiently filtered by liver, spleen, and bone marrow, thus a size between 10 and 200 nm would enable liposomes to circulate in the bloodstream . Due to their structure, liposomes have demonstrated their ability as nanocarriers for CNS targeting of hydrophilic or lipophilic cytotoxics, neuroprotectants, antiepyleptics, anti-ischemia, antiretroviral and antifungals drugs among others, and diagnostic agents. Basically, liposomes deliver their cargo across the BBB through passive and active targeting (Figure 2). Nonetheless, active targeting goes further, opening a stimuli-responsive strategy.
5.1. Passive targeting strategy
Passive targeting is mainly based on the enhanced permeability and retention (EPR) effect. In 1986, Maeda and co-workers named EPR effect to the mechanism in which macromolecules with a high molecular weight, 15000 to 70000 daltons, such as polymers and proteins precipitate and accumulate effectively in tumor tissues . Such high accumulation usually last more than 24 hours . This phenomenon was attributed to the hypervasculature and enhanced vascular permeability in solid tumors, which is due to the overproduction of vascular mediators including bradykinin, nitric oxide (NO), vascular endothelial growth factor (VEGF) and carbon monoxide (CO) . Moreover, solid tumors have defective blood vessels with large gaps, up to 1.0 μm between endothelial cells, whereby macromolecules pass to the tumor . Since solid tumors lack adequate lymphatic drainage, there is therefore a poor circulatory recovery of the extravasated macromolecules, resulting in their accumulation in the tumor microenvironment for long periods . This phenomenon was not observed in healthy blood vessels ; hence, it constituted a promising strategy to treat selectively cancer solid tumors using nanocarriers like polymer-coated liposomes . Prolonged blood circulation may allow a longer interaction time between liposomes and the target. The incorporation of soluble, hydrophilic, flexible and biocompatible polymers such as polyethylene glycol (PEG) or its derivatives within the bilayer of conventional liposomes leads to the formation of a protective and hydrophilic layer on their surface. This prevents the recognition of liposomes by opsonins and reduces their clearance by the reticuloendothelial system (RES) and consequently extends the liposomal half-life . Other prominent synthetic polymers with stealth properties are poly(vinyl pyrrolidone) (PVP) and poly(acryl amide) (PAA) . Liposomes size is another parameter with high impact on the passive targeting through the EPR effect. Long-circulating liposomes also called stealth liposomes should possess a size inferior to 400 nm for effective extravasation [14, 48]. Different studies demonstrated that passive targeting provides promising therapeutic outcomes in diseases where there is a BBB disruption like stroke [49, 50].
5.2. Active targeting strategy
In the last few years, more sophisticated liposomes were designed to actively target the brain. Active targeting lies on the coupling of targeting moieties including small-molecule ligands, peptides, aptamers, monoclonal antibodies (mAbs) or their fragments on the liposomal surface. Then these functionalized liposomes are able to target the brain after recognizing the biochemical transport systems expressed at the brain endothelial cells. Such systems are the adsorptive-mediated endocytosis (AME), the carrier-mediated transport (CMT), and the receptor-mediated endocytosis (RME). Brain targeting through AME is based on the electrostatic interaction between a positively charged moiety and the negatively charged sites on the luminal surface of plasma membrane and brain capillaries. For instance, cationized human serum albumin conjugated to PEGylated liposomes showed a rapidly time-dependent response taken up by cultured porcine brain capillary endothelial cells and by intact brain capillaries . However,
5.3. Stimuli-responsive strategy
Usually the challenge is to formulate liposomes which have the right size and structure to entrap their cargo with high efficiency and in such a way that they do not leak out. On the other hand, it is important to play on the fluidity of the liposomal membrane. A too high liposomal stability is rather disadvantageous than desired. Remaining inside the stable liposomes, the encapsulated compounds are not delivered to the targeted tissue. At that point, it is necessary to find the right balance between stability in the bloodstream and a high delivery of liposomal cargo in the target. In general, the chemical and biophysical properties of lipid molecules primarily dictate the development of tunable (stimuli-sensitive) liposomes . The various types of stimuli that could trigger liposomal cargo release can be classified into internal or intrinsic to the target tissue (changes in pH, temperature, redox condition, or the activity of certain enzymes) and external or artificially applied (magnetic field, ultrasound, and various types of irradiation) . In one example, the lower pH, the higher temperature, and overexpression of several proteolytic enzymes of the tumor microenvironment should trigger the cytotoxic release when liposomes are exposed . More exhaustive literature about stimuli-sensitive liposomes was formerly described [14, 15].
The encapsulation of nanoparticles in liposomes not only adds more stimuli for delivery but also provides more useful properties. For instance, by encapsulating PEG-coated quantum dots (QDs) in the internal aqueous phase of liposomes, a more extensive fluorescent staining is observed in a solid tumor model compared to free PEGylated QDs . Meanwhile, superparamagnetic iron oxide nanoparticles (SPIONs) loaded in liposomes demonstrated to serve as a magnetic resonance imaging
6. Liposomes for drug delivery to the central nervous system
More recent and relevant studies applying different liposomal targeting strategies for the treatment of major CNS diseases are summarized herein.
An ischemic stroke occurs because of an obstruction, by a blood clot, within a blood vessel supplying blood to the brain . Ischemic stroke accounts for 87% of all stroke cases. The cerebral ischemic area is composed of the ischemic core, a zone of irreversibly damaged tissue, and the ischemic penumbra, a surrounding zone of less severe and reversible damaged tissue . To date, the only Food and Drug Administration (FDA) approved treatment for ischemic stroke is tissue plasminogen activator (tPA), a proteolytic enzyme. tPA enhances the conversion of plasminogen to plasmin, which subsequently degrades the fibrin matrix in the clot and improves blood flow to the ischemic region . However, its short half-life, 2–6 minutes and therapeutic time window, less than 4.5 hours, elicite its administration in high doses which might lead to significant hemorrhagic complications [69, 70]. Interestingly, hemorrhage was reduced when tPA was loaded in actin-targeted liposomes and intravenously administered by the internal carotid artery in an
|Disease||Year||Size (nm)||Targeting ligand||Drug/diagnose agent||Administration route||Results||Refs.|
|Stroke||2015||̴100||HAIYPRH (T7) peptide||ZL006||Intravenous||Increased liposomal transport across the BBB, reduced infarct volume and improved neurological deficit|||
|2013||̴160||Anti-NR1-receptor antibody||Superoxide dismutase enzyme||Intracarotid||Reduced infarct volume, inflammatory markers, and improved |||
|2010||60–90||CDP-Choline||Intravenous||Reduced ischemia-reperfusion in young and aged animals|||
|2010||̴105||Transferrin||VEGF||Intravenous||Reduced infarct volume and increased neovascularization|||
|2003||200–250||Antiactin antibody||tPA||Intravenous||Reduced tPA-induced hemorrhage|||
|2013||̴100||Anti-HSP72 antibody||Citicoline/gadolinium or rhodamine||Intravenous||Increased liposomal transport across the BBB and reduced infarct volume|||
|Cancer||2016||̴110||PTD peptide||Epirubicine and celecoxib||Intravenous||Increased liposomal transport across the BBB, survival time and anti-vasculogenic mimicry effects|||
|2015||100-120||R8-dGR peptide||Paclitaxel||Intravenous||Increased survival time|||
|2015||̴110||R8-c(RGD)||Paclitaxel||Intravenous||Increased survival time and anti-vasculogenic mimicry and anti-brain cancer stem cells effects|||
|2014||̴95||Glutathione||Doxorubicin||Intravenous||Increased doxorubicin levels in brain, tumor growth inhibition, and increased survival|||
|2014||̴100||Glutathione||Doxorubicin||Intravenous||Increased doxorubicin levels in brain|||
|2014||105||WGA||Daunorubicin, quinacrine and tamoxifen||Intravenous||Increased liposomal transport across the BBB and survival time|||
|2014||̴120||RGD and transferrin||Paclitaxel||Intravenous||Increased liposomal transport across the BBB and antiproliferative activity against C6 cells|||
|2013||̴180||Transferrin and folate||Doxorubicin||Intravenous||Increased tumor growth inhibition, survival time, and apoptotic activity in glioma cells|||
|2009||100-110||WGA||Topotecan and tamoxifen||Intravenous||Increased survival time|||
|2015||̴100||pH-sensitive valve||Gd-DTPA||Intravenous||Improved cargo release in tumor microenvironment|||
|2014||̴120||Endoglin||Gd||Intravenous||Increased signal emmited by Gd in tumor periphery|||
|2016||̴180||(RGD-TPGS||Docetaxel/QD||Intravenous||Increased docetaxel levels and QD fluorescence in brain|||
|AD||2015||̴200||Transferrin||α-Mangostin||Intravenous||Increased α -mangostin levels in brain|||
|2015||̴110||Glutathione||Amyloid-targeting antibody fragments||Intravenous||Increased amyloid-targeting antibody fragments levels in plasma and brain|||
|2013||̴180||CPP||Rivastigmine||Intranasal||Increased rivastigmine levels in hippocampus and cortex|||
|2012||̴150||DSPE-PEG3400-XO4||DSPE-PEG3400-XO4||Intravenous||Liposomal transport across the BBB and binding to Aβ plaques|||
|PD||2012||̴120||OX26||GDNF||Intravenous||A partial rescue of nigra-striatal neurons|||
|2011||̴110||Chlorotoxin||L-dopa||Intraperitoneal||Increased dopamine levels in substantia nigra and striata and attenuated behavioral disorders|||
Globocan 2012 revealed that the worldwide brain and CNS cancer incidence and mortality in both sexes was 3.4 and 2.5 per 100,000 people, respectively . In parallel, the World Cancer Research Fund International (http://www.wcrf.org) estimated that 256,000 new cases of brain and CNS cancer were diagnosed in 2012. Gliomas are tumors that arise from glial or precursor cells and include astrocytoma, glioblastoma, oligodendroglioma, ependymoma, mixed glioma, malignant glioma, and a few rare histologies. Glioma accounts for 27% of all tumors and 80% of malignant tumors, and among these, glioblastoma is the most common accounting for 46.1% . Unfortunately, the efficacy of conventional chemotherapy is always limited due to the poor specificity in targeting cancer, low circulation time, reduced penetration in the tissue, and most importantly the toxic side effects of anti-cancer drugs . Thus, nanotechnology appeared to help chemotherapy to be reborn and Doxil®, liposomal doxorubicin, received the first approval as a nano-drug in 1995 . Nowadays, several research groups are developing nanocarriers to encapsulate anti-cancer drugs and fight against cancer tumors. Owing to the leaky nature of the tumor-associated blood vessels and lack of adequate lymphatic drainage, nanocarriers may take advantage of the EPR effect to target tumors . However, in the case of brain tumors, nanocarriers must first overcome the BBB, which remains intact at the early stage of the brain tumor development. Only when the tumor grows to a certain volume and angiogenesis begins, the BBB is impaired and the blood-brain tumor barrier (BBTB) then becomes the main obstacle that nanocarriers must circumvent. Hence, the presence of receptors on the BBB and BBTB provides a pathway to actively target brain tumors (Table 1) . A recent
6.3. Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative dementia and contributes to 65% of all cases. AD is substantially increased among people aged 65 years or older, leading to progressive decline in memory, thinking, language, and learning capacity . The pathophysiology of AD is related to the injury and death of neurons caused by the progressive production and accumulation of insoluble proteins aggregates, such as amyloid-β (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau . Currently, there is no drug to treat AD; only four FDA-approved compounds are known to relieve AD symptoms. These are donepezil, galantamine, memantine, and rivastigmine . Once donepezil, a weak P-gp substrate , was encapsulated in PEGylated liposomes and administered by intranasal route in experimentation animals, it exhibited higher plasma and brain concentrations than free donepezil administered by the same or oral route . In addition, histopathological examination showed that PEGylated liposomal donepezil was safe and non-toxic . Rivastigmine was encapsulated in PEGylated liposomes functionalized with a cell penetrating peptide (CPP), whose proved internalization pathway across the cell membrane is via transduction or endocytosis [92, 93]. This formulation administered by intranasal route demonstrated its capacity to improve rivastigmine distribution and retention in the hippocampus and cortex, which are CNS regions highly affected by AD. This is in comparison with the intravenous administration of rivastigmine solution . The clinical utility of galantamine, which is also a P-gp inhibitor , is hampered by its intricate transport across the BBB and its poor retention in the CNS. Hence, galantamine was loaded in PEGylated liposomes functionalized with a synthethic peptide, Lys-Val-Leu-Phe-Leu-Ser . The selected peptide possess a 75% similar sequence to the serpin enzyme complex-receptor (SEC-R), which is expressed on the surface of neural (PC12) cells and may interact with soluble and non-toxic Aβ-peptides . Thus, fluorometry and confocal microscopy confirmed that actively targeted liposomes significantly facilitated a higher uptake and accumulation of galantamine in PC12 neuronal cells related to non-targeted PEGylated liposomes . The utility of neuroprotective agents in AD was also optimized by encapsulating them in actively targeted liposomes (Table 1).
6.4. Parkinson’s disease
Parkinson’s disease (PD) is the second most common progressive neurodegenerative brain disorder of insidious onset. This chronic disease is caused by a selective degeneration of dopaminergic neurons in the substantia nigra pars compacta, which consequently results in a reduction in striatal dopamine levels . PD is generally characterized by primary motor symptoms such resting tremor, bradykinesia, rigidity, and postural instability. Non-motor symptoms experienced by PD patients may include cognitive impairment, mood disorders, and sleep disturbances . Up-to-date, there is no cure for PD, the only available treatment, dopamine, is focused on the signs and symptoms. Since exogenous dopamine cannot cross the BBB, the gold standard therapy for PD is based on the administration of the natural precursor of dopamine, L-dopa, to restore dopaminergic transmission . Because L-dopa is a P-gp substrate , it only crosses the BBB to a certain extent and once in the brain, it is converted to dopamine. However, L-dopa cannot be administered alone because it is catalyzed to dopamine by peripheral dopamine-decarboxylase enzyme and causes peripheral side effects, such as nausea, sleepiness, and dyskinesia . Thus, L-dopa was encapsulated in PEGylated and chlorotoxin-functionalized liposomes and studied in an
Epilepsy is a chronic and often progressive brain disorder, characterized by recurrent seizures, which are brief episodes of involuntary movement involving a part or the whole body. These episodes are caused by excessive electrical discharges from cortical neurons, which can cause visual disturbances, loss of control of bowel or bladder function, and consciousness . According to the World Health Organization, epilepsy affects about 50 million people worldwide but only 70% of patients can be successfully treated while about 30% of patients are resistant or refractory to current available antiepileptics . Earlier research has shown that mainly the activity of the P-gp at the BBB is directly related to anticonvulsants resistance . This so-called medically intractable epilepsy is often associated with a poor prognosis, increased morbidity and mortality in patients, and a negative social impact in the life of patients and their family environment . Unfortunately, only few studies have tried to improve the epilepsy therapy by applying nanotechnology. In a pilocarpine-induced seizure
7. Liposomes for diagnostics of central nervous system diseases
Liposomes by themselves do not have any imaging property but various efforts have enabled liposomes to entrap and deliver diagnostic agents in pathological tissues. Most investigations deal with diagnosis of cancer.
By attaching synthetic pH-responsive chemical modulators to an
8. Liposomes for theranostics of central nervous system diseases
A major achievement of nanomedicine in the last few years was the development of theranostic delivery systems, which integrate imaging and therapeutic functions in one single but complex structure, thus providing a powerful approach to improve disease-specific detection, treatment, and follow-up monitoring . The flexible composition of liposomes enables them to be engineered to adsorb, entrap, encapsulate, or conjugate different imaging agents and therapeutic compounds .
Citicoline (CDP-Choline), a drug used in the treatment of stroke , was loaded in liposomes made of phospholipids containing rhodamine or gadolinium, which enabled the nanocarriers to be traceable by fluorescence or MRI. These liposomes were functionalized with anti-HSP72 antibody, which is able to bind the HSP72 protein. HSP72 protein is a biomarker expressed for up to seven days in the peri-infarct region following cerebral ischemia . This formulation was administered by intravenous route after surgery in an MCA
Liposomes co-encapsulating the cytotoxic and P-gp substrate docetaxel  and QDs and actively targeted with arginine-glycine-aspartic acid peptide -
8.3. Parkinson’s disease
QDs and apomorphine, a rescue medication for Parkinson’s disease were encapsulated in PEGylated liposomes . Then,
9. Future outcomes
Nanomedicine has emerged as the key to open the door of the medicine of tomorrow. Thanks to exponential efforts and improvements, nanomedicine has launched to the clinical field various drug-loaded liposomes for brain targeting (Table 2). However, regarding other CNS diseases, nanomedicine has not yet fulfilled its promise. The possible improved brain distribution of various liposomal therapeutic compounds and diagnostic agents remains to be studied. The CNS is so complex that gives us a wide variety of receptors to target. Currently, various targeting moieties such as aptamers, peptides, mAbs, or their fragments have proved their ability to target a specific receptor in the CNS. Thus, future studies should investigate their
|Therapeutic compound||Purpose: to assess||Patients||Phase|
|Cytarabine (DepoCyte®)||The safety of whole brain radiotherapy||Brain metastases||I|
|Cytarabine||The effectiveness in co-administration with high doses of methotrexate||SNC metastases||II|
|Doxorubicin||The effectiveness||Refractory solid brain tumors||I|
|Vincristine (Marqibo)||The safety, activity, and pharmacokinetics||Refractory solid brain tumors in children and adolescents||I/II|
|Doxorubicin (2B3-101)||The safety, tolerability, and pharmacokinetics alone or in combination with trastuzumab||Solid tumors and brain metastases or recurrent malignant glioma||I/IIa|
Nanomedicine and especially liposomes represent a step forward to deliver diagnostic agents and/or therapeutic compounds in CNS diseases such as stroke, brain cancer, AD, PD, or epilepsy. Therefore, this manuscript outlines the most recent and relevant engineered liposomal strategies to cirvumvent the BBB and its main efflux transporter, the P-gp. Moreover, important aspects to further optimize liposomal strategies are discussed at the end of this chapter.